Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov;159(3):414-416.
doi: 10.1111/jnc.15467. Epub 2021 Jul 23.

Iron reduces the propagation of pathological α-synuclein: An Editorial Highlight for "Brain iron enrichment attenuates α-synuclein spreading after injection of preformed fibrils" on page 554

Yu-Jie Guo  1   2 , Scott Ayton  3   4   5 , Peng Lei  1
Affiliations
Editorial

Iron reduces the propagation of pathological α-synuclein: An Editorial Highlight for "Brain iron enrichment attenuates α-synuclein spreading after injection of preformed fibrils" on page 554

Yu-Jie Guo et al. J Neurochem. 2021 Nov.

Abstract

Iron accumulation and α-synuclein aggregates (e.g., Lewy bodies) have been linked with the pathogenesis of Parkinson's disease (PD), with yet-to-be-determined interaction. Previous studies have indicated that iron binds to α-synuclein and triggers its aggregation in vitro, and iron is found enriched in Lewy bodies. In the current study, Joppe et al. have found that the propagation of pathological α-synuclein caused by intrastriatal α-synuclein preformed fibrils (PFFs) injection was unexpectedly attenuated in rodent brains in a model of brain iron elevation (neonatal iron feeding). PFFs stimulated microglial activation was also reduced in mice with elevated iron. These results may provide new insight into the complex interaction between these two key pathologies of PD.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Angelova, P. R., Choi, M. L., Berezhnov, A. V., Horrocks, M. H., Hughes, C. D., De, S., Rodrigues, M., Yapom, R., Little, D., Dolt, K. S., Kunath, T., Devine, M. J., Gissen, P., Shchepinov, M. S., Sylantyev, S., Pavlov, E. V., Klenerman, D., Abramov, A. Y., & Gandhi, S. (2020). Alpha synuclein aggregation drives ferroptosis: An interplay of iron, calcium and lipid peroxidation. Cell Death and Differentiation, 27, 2781-2796. https://doi.org/10.1038/s41418-020-0542-z
    1. Ayton, S., & Lei, P. (2014). Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. BioMed Research International, 2014, 1-9. https://doi.org/10.1155/2014/581256
    1. Ayton, S., Lei, P., Duce, J. A., Wong, B. X., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013). Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Annals of Neurology, 73, 554-559. https://doi.org/10.1002/ana.23817
    1. Ayton, S., Lei, P., Hare, D. J. et al (2015). Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. Journal of Neuroscience, 35, 3591-3597.
    1. Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., Duhamel, A., Jissendi, P., Dujardin, K., Auger, F., Ravasi, L., Hopes, L., Grolez, G., Firdaus, W., Sablonnière, B., … Bordet, R. (2014). Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxidants & Redox Signaling, 21, 195-210. https://doi.org/10.1089/ars.2013.5593

LinkOut - more resources